Ligand为拟议的5.5亿美元可转换优先票据定价

2026-06-22 19:33

Ligand Pharmaceuticals (LGND) said on Monday it plans to offer $550M of convertible senior notes due 2031 in a private placement and expects to grant initial purchasers a 13-day option to buy up to an additional $82.5M of notes.
The notes will be senior unsecured obligations and will pay interest semiannually beginning March 15, 2027.
The company expects to use up to $75M of the proceeds to repurchase shares from certain note purchasers in privately negotiated transactions.
Remaining proceeds will be used for general corporate purposes, including strategic investments and the previously announced acquisition of Xoma Royalty.
Ligand expects to enter into convertible note hedge and warrant transactions to mitigate potential dilution from note conversions.
The warrant transactions could be dilutive if Ligand's share price exceeds the warrants' strike price.

More on Ligand Pharmaceuticals